FIGS (FIGS) AI Stock Analysis

• Market Cap: $845.27M
• Dividend Yield: N/A
• Average Volume (3M): 1.85M
• Price to Earnings (P/E): 866.7
• Beta (1Y): 0.95
• Revenue Growth: 3.02%
• EPS Growth: -94.52%
• Country: US
• Employees: 303
• Sector: Consumer Cyclical
• Sector Strength: 59
• Industry: Apparel - Manufacturers
• EPS (TTM): 0.00
• Shares Outstanding: 154,267,490
• 10 Day Avg. Volume: 1,643,954
• 30 Day Avg. Volume: 1,850,930
• PEG Ratio: 0.00
• Price to Book (P/B): 3.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.81
• Enterprise Value/Market Cap: 1.15
• Enterprise Value/Revenue: 0.44
• Enterprise Value/Gross Profit: 2.58
• Enterprise Value/Ebitda: 18.16
• 1Y Price Target: $4.63
• Price Target Upside: -10.96% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 7

• Rating: 68 Neutral
• Price Target: $5.00 ▼(-3.85%Downside)

FIGS shows a strong balance sheet and strategic revenue growth. However, high P/E ratio and mixed technical indicators highlight valuation concerns and potential market weakness. Strategic investments and leadership changes provide a positive outlook, but challenges like tariffs and margin pressures remain risks.

Positive Factors

International Expansion

International revenue is a key growth driver, with expansion plans into Japan and South Korea.

Sales Growth

Sales trends have remained positive with an increase in both new and reactivated customers.

Negative Factors

Consumer Weakness

FIGS has been impacted by a weakening consumer with revenue flat year over year.

Margin Pressure

Margin pressure is expected to continue as tariffs and promotional activities affect profitability.

Stock Performance

The stock has underperformed, declining -15% YTD and -73% since its IPO.

FIGS Business Overview & Revenue Model

Company Description

FIGS, Inc. operates as a direct-to-consumer healthcare apparel and lifestyle company in the United States. It designs and sells healthcare apparel and other non-scrub offerings, such as lab coats, under scrubs, outerwear, activewear, loungewear, compression socks footwear, and masks. It also offers sports bras, performance leggings, tops, super-soft pima cotton tops, vests, and jackets. The company markets and sells its products through its digital platform comprising website and mobile app. FIGS, Inc. was founded in 2013 and is headquartered in Santa Monica, California.

How the Company Makes Money

FIGS makes money primarily through the direct-to-consumer sales of its medical apparel products, such as scrubs, lab coats, underscrubs, outerwear, activewear, loungewear, and accessories. The company operates an e-commerce platform, which is its main channel for reaching customers, allowing it to bypass traditional retail markups and offer competitive pricing. FIGS focuses on building brand loyalty through high-quality products and community engagement with healthcare professionals. Additionally, the company benefits from customer word-of-mouth and targeted marketing strategies, which contribute to its growing customer base and revenue. While FIGS does not currently report significant partnerships as a major revenue factor, its innovative product offerings and strong consumer base are key contributors to its financial success.

FIGS Financial Statement Overview

Summary

FIGS maintains a strong balance sheet with low leverage and high equity ratios, indicating financial stability. However, profitability margins are slim, and there's a challenge in sustaining cash flow growth.

Income Statement

FIGS shows a strong gross profit margin of 67.1% TTM, reflecting efficient cost management. However, the company faces challenges in net profit margin, which is only 0.2% TTM, indicating slim overall profitability despite revenue growth of 1% TTM. EBIT and EBITDA margins remain low at 0.3% and 1.1% respectively, suggesting pressure in operational efficiency.

Balance Sheet

FIGS maintains a robust balance sheet with a debt-to-equity ratio of 0.13, indicating low leverage. The equity ratio is strong at 73%, showcasing financial stability. Return on equity stands at 0.3% TTM, which is modest but shows potential for improvement.

Cash Flow

FIGS demonstrates positive cash flow management with an operating cash flow to net income ratio of 66.6 TTM, reflecting effective cash generation relative to earnings. Free cash flow to net income is high at 51.5 TTM, although free cash flow growth is negative at -5% TTM, suggesting challenges in sustaining cash flow momentum.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
561.17M	555.56M	545.65M	505.83M	419.59M	263.11M
	Gross Profit
376.83M	375.62M	376.96M	354.46M	301.22M	190.22M
	EBIT
1.61M	2.27M	34.05M	37.67M	10.98M	57.94M
	EBITDA
6.24M	8.96M	36.99M	39.59M	11.52M	58.89M
	Net Income Common Stockholders
1.18M	2.72M	22.64M	21.19M	-9.56M	49.76M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
251.21M	245.11M	246.69M	159.78M	195.37M	58.13M
	Total Assets
522.31M	509.79M	473.21M	395.06M	311.75M	133.85M
	Total Debt
51.33M	53.03M	47.11M	19.16M	0.00	0.00
	Net Debt
-38.68M	-32.62M	-97.06M	-140.61M	-195.37M	-58.13M
	Total Liabilities
140.78M	132.66M	96.36M	87.33M	66.18M	36.18M
	Stockholders Equity
381.54M	377.13M	376.85M	307.74M	245.57M	97.68M
Cash Flow		Free Cash Flow
60.94M	64.14M	84.57M	-40.68M	63.73M	19.49M
	Operating Cash Flow
78.78M	81.16M	100.92M	-35.33M	66.44M	21.75M
	Investing Cash Flow
-96.63M	-94.92M	-117.19M	-5.85M	-2.71M	-2.26M
	Financing Cash Flow
-47.46M	-44.77M	670.00K	3.52M	75.57M	294.00K

FIGS Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FIGS, the sentiment is Positive. The current price of 5.2 is above the 20-day moving average (MA) of 4.69, above the 50-day MA of 4.42, and below the 200-day MA of 5.33, indicating a neutral trend. The MACD of 0.19 indicates Negative momentum. The RSI at 69.73 is Neutral, neither overbought nor oversold. The STOCH value of 89.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FIGS.

FIGS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AIN	73 Outperform	$2.07B	27.59	8.32%	1.55%	1.17%	-30.24%
FIGS	68 Neutral	$845.27M	866.67	0.31%	―	3.02%	-94.52%
Sector *	63 Neutral	$6.98B	11.41	2.80%	4.24%	2.68%	-24.94%
UA	62 Neutral	$2.86B	―	-9.95%	―	-7.47%	-131.70%
GIII	60 Neutral	$954.89M	5.04	12.21%	―	1.72%	13.75%
UFI	53 Neutral	$96.39M	―	-15.73%	―	2.51%	32.95%
OXM	47 Neutral	$814.24M	9.32	15.71%	5.04%	-3.49%	52.67%

FIGS Corporate Events

FIGS Holds Annual Stockholders Meeting via Webcast

On June 4, 2025, FIGS, Inc. held its annual meeting of stockholders via live webcast, where a quorum was established with over 95% of the combined voting power of its Class A and Class B common stock. During the meeting, stockholders elected three Class I directors to serve until 2028, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the compensation of the company’s named executive officers on a non-binding basis.

The most recent analyst rating on (FIGS) stock is a Buy with a $7.25 price target. To see the full list of analyst forecasts on FIGS stock, see the FIGS Stock Forecast page.

FIGS Reports Q1 2025 Revenue Growth Amid Tariff Challenges

On May 8, 2025, FIGS, Inc. announced its first quarter 2025 financial results, reporting a net revenue increase of 4.7% year over year, driven by higher orders from existing customers and increased average order value. Despite a decrease in gross margin and adjusted EBITDA, the company showed signs of growth in the U.S. and international markets, with a notable 16.4% rise in international net revenues. FIGS updated its full-year 2025 outlook to account for U.S. tariff impacts, highlighting the company’s strategic focus on maintaining its market leadership amidst economic uncertainties.

FIGS Appoints Jerry Jao as Independent Director

On April 1, 2025, FIGS, Inc., a leading healthcare apparel brand, appointed Jerry Jao as an independent director to its board, also naming him Chair of the Audit Committee and a member of the Compensation Committee. Jao, with extensive experience in marketing, technology, and finance, is expected to contribute valuable insights to accelerate FIGS’ growth and enhance its board’s functionality, particularly in digital marketing and AI solutions.